Technical Analysis for LGND - Ligand Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade F 114.81 0.30% 0.34
LGND closed up 0.3 percent on Wednesday, May 22, 2019, on 56 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Flat
See historical LGND trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Spinning Top Other 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup 0.30%
Oversold Stochastic Weakness 0.30%
New Downtrend Bearish 1.98%
Oversold Stochastic Weakness 1.98%
Doji - Bullish? Reversal 0.11%
Oversold Stochastic Weakness 0.11%
Slingshot Bearish Bearish Swing Setup -1.09%

Older signals for LGND ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company's assets include PROMACTA, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Viviant/Conbriza for the treatment of postmenopausal osteoporosis; Nexterone, an injectable formulation; and Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis. Its late-stage development programs comprise PROMACTA, which is in is in Phase II clinical studies for the treatment of oncology-related thrombocytopenia in patients with solid tumors, sarcoma, and Myelodysplastic Syndrome. The company's late-stage development programs also include Merck Captisol program that is in Phase III studies; Captisol-enabled Clopidogrel, which is in Phase III studies; RE-021 program, a dual acting receptor antagonist that is in various stages of development for indications of severe kidney diseases; Dinaciclib that is in Phase IIb/III adaptive clinical trials for the treatment of patients with refractory chronic lymphocytic leukemia; and Beta-Secretase Inhibitor, which is in Phase II/III studies for treating Alzheimer's disease. In addition, its late-stage development programs comprise Captisol-enabled Delafloxacin, a Phase III clinical trial product for the management of acute seizure disorder; and Captisol-enabled Delafloxacin that is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. The company has alliances with GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly and Co., Spectrum Pharmaceuticals, and The Medicines Company. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.
Biotechnology Pain Chemical Compounds Organic Compounds Solid Tumors Alzheimer's Disease Multiple Myeloma Chloroarenes Myelodysplastic Syndrome Clinical Trial Product Phenols Skin And Skin Structure Infections Carboxylic Acids Selective Estrogen Receptor Modulators
Is LGND a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 278.62
52 Week Low 98.56
Average Volume 386,610
200-Day Moving Average 163.0543
50-Day Moving Average 122.565
20-Day Moving Average 119.5975
10-Day Moving Average 114.848
Average True Range 4.2906
ADX 25.0
+DI 16.012
-DI 24.865
Chandelier Exit (Long, 3 ATRs ) 117.2682
Chandelier Exit (Short, 3 ATRs ) 124.3718
Upper Bollinger Band 129.9836
Lower Bollinger Band 109.2114
Percent B (%b) 0.27
BandWidth 17.368423
MACD Line -2.7879
MACD Signal Line -2.2596
MACD Histogram -0.5283
Fundamentals Value
Market Cap 2.42 Billion
Num Shares 21.1 Million
EPS 0.41
Price-to-Earnings (P/E) Ratio 280.02
Price-to-Sales 25.74
Price-to-Book 7.36
PEG Ratio 1.53
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 120.03
Resistance 3 (R3) 119.78 117.78 119.16
Resistance 2 (R2) 117.78 116.45 117.91 118.87
Resistance 1 (R1) 116.30 115.63 117.04 116.55 118.58
Pivot Point 114.30 114.30 114.68 114.43 114.30
Support 1 (S1) 112.82 112.97 113.56 113.07 111.04
Support 2 (S2) 110.82 112.15 110.95 110.75
Support 3 (S3) 109.34 110.82 110.46
Support 4 (S4) 109.59